CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, today announced that the Company will present preliminary results from the ongoing Phase 1 ATTCK-20-03 study, testing ACTR707 in combination with rituximab in patients with relapsed/refractory CD20+ B cell lymphoma (r/r/ NHL), and the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in combination with SEA-BCMA in patients with relapsed/refractory multiple myeloma (r/r MM), at the upcoming American Society of Hematology (ASH) meeting taking place December 1-4, 2018, in San Diego, CA.
“Preliminary data from these two trials demonstrate ACTR T cell activity and a well-tolerated safety profile of both ACTR707 and ACTR087 product candidates in their respective patient populations,” said Michael Vasconcelles, Chief Medical Officer of Unum. “We remain encouraged by the emerging potential best-in-class profile of ACTR707 in combination with rituximab in patients with r/r NHL and the early safety data of ACTR087 in combination with the novel antibody, SEA-BCMA, in patients with r/r MM.”
Data from the first dose level in the multicenter Phase 1 study, ATTCK-20-03, testing ACTR707 in combination with rituximab in patients with relapsed or refractory CD20+ B cell lymphoma, was presented in September 2018 at the Fourth Annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. Three of the six patients treated at the first dose level in the study achieved a complete response, two of which remained ongoing at the time of the September 4, 2018 data cut off. No dose-limiting toxicities (DLTs) were observed in any of the four DLT-evaluable patients, and no serious or severe adverse events of cytokine release syndrome or neurotoxicity were observed in any patients. Updated data from this cohort, along with data on the subsequent dose cohort will be presented at the ASH meeting.
In addition, first-in-human dosing of single agent SEA-BCMA, and of ACTR087 in combination with SEA-BCMA, in the ATTCK-17-01 multi-center Phase 1 dose-escalation study was well tolerated, with no dose-limiting toxicities in the first two single-subject cohorts. Following infusion, ACTR+ T cells were detectable in these patients and demonstrated expansion post infusion. These data have supported the continued dose escalation of ACTR087 in combination with SEA-BCMA. Updated data from the first three dose cohorts of the trial will be presented at the ASH meeting, with subsequent updates anticipated in 2019.
Details on the presentations are as follows:
Presentation Title: Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-tumor activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-cell Lymphoma
Session Title: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Poster II
Date & Time: Sunday, 2 December, 2018 from 6:00 - 8:00pm
Location: San Diego Convention Center, Hall GH
Presentation Title: A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T cell Receptor, in Combination With SEA-BCMA, a Novel Non-fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Session Title: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Date & Time: Saturday, December 1, 2018 from 6:15 – 8:15pm
Location: San Diego Convention Center, Hall GH
About Unum Therapeutics
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Unum’s novel proprietary technology, antibody-coupled T cell receptor (ACTR) is a universal, engineered cell therapy intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. ACTR087 and ACTR707, each used in combination with rituximab, an anti-CD20 antibody, are Unum’s two most advanced product candidates, currently in Phase 1 clinical testing in adult patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The Company has an additional product candidate in Phase 1 clinical testing: ACTR087 used in combination with the novel antibody SEA-BCMA in adult patients with relapsed or refractory multiple myeloma. Finally, the Company has an active investigational new drug application (IND) for ACTR707 used in combination with trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) antibody, to treat patients with HER2+ advanced cancer. This Phase 1 trial is expected to be initiated by the end of 2018.
The Company is headquartered in Cambridge, MA.
Forward looking Statements
This press release contains forward-looking statements. Statements in this press release about our future expectations, plans and prospects, our long-term growth and our ability to achieve our strategy, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates, including the four lead ACTR product candidates, the results of our clinical trials, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the accuracy of our estimates regarding expenses, future revenues, capital requirements, and the need for additional financing, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
Stephanie Ascher, 212-362-1200
Paul Kidwell, 617-680-1088